Screener
Arcutis Biotherapeutics, Inc. ARQT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
FAQ
- What is Arcutis Biotherapeutics, Inc.'s accounts receivable?
- Arcutis Biotherapeutics, Inc. (ARQT) reported accounts receivable of $155.16M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s accounts receivable changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s accounts receivable increased by 45.4% year-over-year, from $106.69M to $155.16M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s accounts receivable?
- Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s accounts receivable has grown at a 246.6% compound annual growth rate (CAGR), from $10.89M to $453.45M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Arcutis Biotherapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude